Literature DB >> 3367616

Evaluation of the stability of human erythropoietin in samples for radioimmunoassay.

K U Eckardt1, A Kurtz, P Hirth, P Scigalla, L Wieczorek, C Bauer.   

Abstract

Radioimmunoassays for erythropoietin are limited so far to a few specialized laboratories and this requires transport and storage of samples. We therefore tested the stability of immunoreactive erythropoietin in serum and plasma samples obtained from a uremic and a nonuremic anemic patient. No significant change in the concentration of immunoreactive erythropoietin was found in either serum or plasma samples for up to 14 days of storage. This type of stability was observed no matter whether the samples were stored at room temperature, 4 degrees C, or -20 degrees C. There was no difference between the estimates of erythropoietin in serum and heparinized plasma. Validity of the radioimmunoassay used in this study was demonstrated by parallelism of dilution curves of test specimens and the 2nd International Reference Preparation for erythropoietin and by a close correlation between the immunoreactivity and the bioactivity of the hormone, as assessed in the same samples by the exhypoxic polycythemic mouse bioassay. In conclusion the data obtained clearly indicate that the necessity of storage and transport of clinical samples does not limit the practicability of the radioimmunoassay for erythropoietin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3367616     DOI: 10.1007/bf01748163

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  9 in total

1.  Bio-assay of erythropoietin in mice made polycythaemic by exposure to air at a reduced pressure.

Authors:  P M COTES; D R BANGHAM
Journal:  Nature       Date:  1961-09-09       Impact factor: 49.962

2.  The mode of action and nature of a heat stable plasma erythropoietic factor.

Authors:  W A RAMBACH; H L ALT; J A COOPER
Journal:  Blood       Date:  1957-12       Impact factor: 22.113

3.  Effect of chemical and enzymatic agents on the biological activity of erythropoietin.

Authors:  J Espada; N C Brandan; M Dorado
Journal:  Acta Physiol Lat Am       Date:  1973

Review 4.  A rationale for the application of trasylol as a protease inhibitor in radioimmunoassay.

Authors:  E S Zyznar
Journal:  Life Sci       Date:  1981-04-27       Impact factor: 5.037

5.  Erythropoietin titers in anemic, nonuremic patients.

Authors:  A J Erslev; J Wilson; J Caro
Journal:  J Lab Clin Med       Date:  1987-04

6.  Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.

Authors:  J W Eschbach; J C Egrie; M R Downing; J K Browne; J W Adamson
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

7.  Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings.

Authors:  J F Garcia; S N Ebbe; L Hollander; H O Cutting; M E Miller; E P Cronkite
Journal:  J Lab Clin Med       Date:  1982-05

8.  Immunoreactive erythropoietin in serum. I. Evidence for the validity of the assay method and the physiological relevance of estimates.

Authors:  P M Cotes
Journal:  Br J Haematol       Date:  1982-03       Impact factor: 6.998

9.  Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.

Authors:  C G Winearls; D O Oliver; M J Pippard; C Reid; M R Downing; P M Cotes
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

  9 in total
  22 in total

1.  Oxygen-dependent erythropoietin production by the isolated perfused rat kidney.

Authors:  H Scholz; H J Schurek; K U Eckardt; A Kurtz; C Bauer
Journal:  Pflugers Arch       Date:  1991-04       Impact factor: 3.657

2.  Pharmacokinetic-pharmacodynamic modelling of recombinant human erythropoietin in athletes : a population approach.

Authors:  A Gaudard; E Varlet-Marie; M Audran; R Gomeni; F Bressolle
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

3.  Modulation of erythropoietin formation by changes in blood volume in conscious dogs.

Authors:  H Ehmke; A Just; K U Eckardt; P B Persson; C Bauer; H R Kirchheim
Journal:  J Physiol       Date:  1995-10-01       Impact factor: 5.182

4.  Age-dependent expression of the erythropoietin gene in rat liver and kidneys.

Authors:  K U Eckardt; P J Ratcliffe; C C Tan; C Bauer; A Kurtz
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

5.  Serum immunoreactive erythropoietin of children in health and disease.

Authors:  K U Eckardt; W Hartmann; U Vetter; F Pohlandt; R Burghardt; A Kurtz
Journal:  Eur J Pediatr       Date:  1990-04       Impact factor: 3.183

6.  Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.

Authors:  U Gladziwa; U Klotz; K Bäumer; R Zollinger; H Mann; H G Sieberth
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Perioperative plasma erythropoietin levels in hip arthroplasty.

Authors:  A Lorentz; K U Eckardt; P M Osswald; C Kruse
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

8.  Oxygen-dependent expression of the erythropoietin gene in rat hepatocytes in vitro.

Authors:  K U Eckardt; C W Pugh; P J Ratcliffe; A Kurtz
Journal:  Pflugers Arch       Date:  1993-06       Impact factor: 3.657

9.  Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.

Authors:  A Braun; R Ding; C Seidel; T Fies; A Kurtz; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

10.  Lack of transport of erythropoietin across the human placenta as studied by an in vitro perfusion system.

Authors:  A Malek; R Sager; K U Eckardt; C Bauer; H Schneider
Journal:  Pflugers Arch       Date:  1994-05       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.